Comparative Pharmacology
Head-to-head clinical analysis: LOKELMA versus SODIUM ZIRCONIUM CYCLOSILICATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOKELMA versus SODIUM ZIRCONIUM CYCLOSILICATE.
LOKELMA vs SODIUM ZIRCONIUM CYCLOSILICATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Patiromer, a non-absorbed potassium-binding polymer, exchanges calcium for potassium ions in the gastrointestinal tract, thereby increasing fecal potassium excretion and lowering serum potassium levels.
Sodium zirconium cyclosilicate is a non-absorbed, inorganic, potassium-selective cation exchanger that binds potassium ions in the gastrointestinal tract, thereby reducing the absorption of potassium and facilitating its fecal excretion. It exchanges sodium and hydrogen for potassium in the gut lumen.
5 g (one packet) orally three times daily; titrate to maintain serum potassium 4.0-5.0 mEq/L; maximum 15 g three times daily (45 g/day).
5 g orally three times daily.
None Documented
None Documented
Not applicable as LOKELMA is not systemically absorbed; terminal half-life is not measurable in traditional sense. Clinical effect duration correlates with gastrointestinal transit time (~6-8 hours for peak potassium lowering).
Not applicable as the drug acts locally in the GI tract without systemic absorption; clinical effect persists for duration of dosing.
Primarily eliminated unchanged in feces (approximately 90%) via gastrointestinal transit; <1% excreted in urine as absorbed sodium zirconium cyclosilicate is negligible.
Primarily eliminated unchanged in feces (>99%); negligible renal excretion (<1%) as the drug is not absorbed systemically.
Category C
Category C
Potassium Binder
Potassium Binder